Terlipressin is a medicine used to control bleeding from esophageal varices, which are enlarged veins in the esophagus. It's given as an injection. It also helps treat a serious condition called hepatorenal syndrome.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Terlipressin is a prescription medicine given by vein in the hospital to people with serious complications of advanced liver disease. In the United States it is sold as Terlivaz, approved in 2022 to improve kidney function in adults with hepatorenal syndrome (HRS) whose kidney function is falling quickly. It was the first FDA-approved medicine for this condition. Hepatorenal syndrome is kidney failure that develops in people with advanced cirrhosis (severe scarring of the liver), often along with ascites, a buildup of fluid in the abdomen. It is driven by changes in circulation caused by the liver disease: blood vessels in the gut widen, blood pressure falls, and the kidneys' own blood vessels clamp down, so the kidneys receive too little blood. The outlook is poor, particularly when a liver transplant is not possible, so restoring kidney function matters. Outside the United States, terlipressin has long been used to help control bleeding from esophageal varices, swollen veins in the lower esophagus that can burst in people with cirrhosis. In the UK it is sold for this purpose as Glypressin. Terlivaz is not approved for variceal bleeding in the US. Research suggests that drugs of this type used on their own, without endoscopic treatment of the bleeding veins, lead to worse survival than endoscopic treatment, so they are not a substitute for it.
Terlipressin is a synthetic version of vasopressin, a natural hormone that, among other roles, tightens blood vessels. The body gradually converts it into lysine-vasopressin, a more active form, although terlipressin also has some activity of its own. It acts mainly on the receptors that make blood vessels constrict. In advanced cirrhosis, scar tissue raises pressure in the portal vein, which carries blood from the gut to the liver (portal hypertension), and blood vessels in the abdomen widen. Terlipressin narrows those vessels. That lowers portal pressure and returns more blood to the general circulation, which raises blood pressure. With better blood pressure and circulating volume, blood flow to the kidneys can improve. Lower portal pressure is also why it can help slow bleeding from varices. Because it tightens blood vessels throughout the body, it can also reduce blood flow to the heart, intestines, hands and feet. That same action explains its most serious side effects.
Terlivaz is given only in the hospital, as an injection into a vein over about two minutes every six hours. Before the first dose, the team checks blood oxygen level, fluid status and how severe the liver failure is. During treatment, oxygen is tracked continuously with a pulse oximeter, a small clip usually placed on a finger. The dose is guided by serum creatinine, a blood test of kidney function in which a higher number means the kidneys are filtering less well. On day 4, the team compares creatinine with the value before treatment. If it has fallen by at least 30 percent, the same dose continues. If it has fallen less than that, the dose may be doubled. If it has not fallen at all, terlipressin is stopped. When it works, treatment continues until creatinine has been 1.5 mg/dL or lower on two checks, plus one more day, for a maximum of 14 days. In the main trial, people also received albumin, a protein solution given by vein to support blood volume. Where terlipressin is used for variceal bleeding, it follows a different product's instructions: doses every four hours for a short course of up to two days.
In the main trial, the most common side effects were abdominal pain, nausea, diarrhea, shortness of breath and respiratory failure. Fluid overload, fluid around the lungs (pleural effusion), serious infection (sepsis) and a slow heart rate were also more common than with placebo. Headache and low blood sodium (hyponatremia) have been reported since approval. The most serious risk is breathing failure, which can be fatal. In the main trial it occurred in 14 percent of people treated with terlipressin, compared with 5 percent on placebo. Because the drug tightens blood vessels, it can also reduce blood flow to the heart, brain, intestines, or hands and feet. Skin damage and gangrene (death of tissue) have been reported. Warning signs include chest pain, severe or worsening belly pain, and skin, fingers or toes that turn pale, blue or dark. A person receiving terlipressin, or a family member at the bedside, should tell the nurse right away about new or worsening shortness of breath, chest pain, severe belly pain or color changes in the skin. The team stops the drug when these problems are confirmed.
Terlipressin is not started when blood oxygen is low (a pulse oximeter reading below 90 percent) or breathing is getting worse, and it is stopped if oxygen drops below that level during treatment. The risk of breathing failure is higher in people carrying too much fluid and in people with grade 3 acute-on-chronic liver failure (ACLF), a sudden worsening of cirrhosis in which other organs also begin to fail. The label advises avoiding terlipressin in grade 3 ACLF. If fluid builds up, the team cuts back albumin and other IV fluids, uses diuretics (water pills) carefully, and may pause or reduce terlipressin. It is not used when blood flow to the heart, limbs or intestines is already reduced, and is avoided in people with a history of severe heart or blood vessel disease or stroke. For people on a liver transplant list, side effects such as breathing failure or reduced blood flow to the intestines can leave them too ill for transplant. For people already at the top of the list, the label says the benefits may not outweigh the risks. People whose creatinine is above 5 mg/dL are unlikely to benefit. Terlipressin can cause contractions of the uterus and may harm a developing baby; UK labeling says it should not be used in pregnancy. It is not known whether it passes into breast milk. Because the hospital team gives every medicine, it checks interactions, especially with other drugs that slow the heart rate or affect heart rhythm.
Terlipressin is a short hospital treatment, not a long-term medicine. In the main US trial, about 29 percent of people who received it had their creatinine return to 1.5 mg/dL or lower by day 14, compared with about 16 percent on placebo. It helps a meaningful minority of people, but not most, and the day 4 creatinine result is the first clear sign of whether it is working. In the trial, treatment typically lasted about five days. Expect close monitoring the whole time: continuous oxygen readings, frequent blood tests of kidney function and sodium, and careful tracking of fluids. Even when kidney function recovers, hepatorenal syndrome reflects how advanced the liver disease is, and it can come back. Terlipressin does not treat the liver disease itself, so the longer-term plan depends on the liver and on whether a transplant is possible.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Terlipressin, what you've noticed, or ask the community a question.